Garassino, M. C., Gadgeel, S., Novello, S., Halmos, B., Felip, E., Speranza, G., . . . Paz-Ares, L. (2025). Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]. JTO clinical and research reports, 6(10), 100892. https://doi.org/10.1016/j.jtocrr.2025.100892
Chicago-Zitierstil (17. Ausg.)Garassino, Marina C., et al. "Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]." JTO Clinical and Research Reports 6, no. 10 (2025): 100892. https://doi.org/10.1016/j.jtocrr.2025.100892.
MLA-Zitierstil (9. Ausg.)Garassino, Marina C., et al. "Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]." JTO Clinical and Research Reports, vol. 6, no. 10, 2025, p. 100892, https://doi.org/10.1016/j.jtocrr.2025.100892.